In addition, the survival time of patients with PRAD and/containing high ZFC3H1 expression groups was (was becomes ‘were’ if you use the word ‘and’) shorter than that in patients with low ZFC3H1 expression. Here, ZFC3H1 is linked to prostate adenocarcinoma.